The execution of the warrant exercise and distribution-in-kind significantly increases the public float and dilutes existing shareholders. Monitor for further distributions to Sermonix equity owners and any potential secondary sales by PXV II or other recipients, which could pressure the stock price.
Price Chart
Executive Summary
Sermonix Pharmaceuticals exercised a prefunded warrant for 3,149,470 shares of LeonaBio common stock on October 26, 2026, increasing its beneficial ownership to 25.1% of the outstanding shares. The remaining warrant rights for 2,352,932 shares were assigned to Perceptive Xontogeny Venture Fund II as a distribution-in-kind, and Sermonix also declared a distribution-in-kind of 4,725,754 shares to its equity owners, with 170,940 shares assigned to a creditor. This filing reflects the execution of previously disclosed transactions rather than new activist demands or escalation.
Key Financial Metrics
Key Facts
- Sermonix exercised a prefunded warrant for 3,149,470 shares of LeonaBio common stock on 10/26/2026.
- Sermonix's beneficial ownership increased to 25.1% of LeonaBio's outstanding shares, based on 9,421,663 shares outstanding.
- The remaining prefunded warrant rights for 2,352,932 shares were assigned to Perceptive Xontogeny Venture Fund II as a distribution-in-kind.
- Sermonix declared a distribution-in-kind of 4,725,754 shares to its equity owners, including the 2,352,932 assigned to PXV II.
- Sermonix assigned 170,940 shares to a creditor in satisfaction of amounts owed.
- The transactions were previously disclosed in the original Schedule 13D and prior amendments, and this filing is a mechanical update reflecting their execution.
Financial Impact
Sermonix exercised warrants for 3,149,470 shares, representing approximately 33.4% of the then-outstanding shares (9,421,663). The total shares subject to distribution-in-kind (4,725,754) and creditor assignment (170,940) represent substantial dilution to existing shareholders.
Risk Factors
- Substantial dilution from the issuance of 3,149,470 shares upon warrant exercise and the planned distribution of 4,725,754 shares to Sermonix equity owners.
- Potential overhang from the remaining 2,352,932 shares held by PXV II via the assigned prefunded warrant.
- Creditor assignment of 170,940 shares may lead to immediate selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001655566-26-000004 |
| Document: 0001655566-26-000004-index.html | 0001655566-26-000004 |
| Document: 0001655566-26-000004.txt | 0001655566-26-000004 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 1d ago | SC 13D/A | $4.96 | awaiting T+60 | awaiting T+60 | $4.91 (−1.01%) |
Oct 26, 2026 3d ago | SC 13D/A | $4.89 | awaiting T+60 | awaiting T+60 | $4.91 (+0.41%) |
May 11, 2026 24w ago | DEFA14A | $10.17 $7.81 | ▼ −23.21% | ▼ −27.59% | $4.91 (−51.72%) |
May 7, 2026 25w ago | 3 | $10.04 $7.66 | ▼ −23.71% | ▼ −28.54% | $4.91 (−51.10%) |
Apr 23, 2026 27w ago | Press Release | $8.33 $7.98 | ▼ −4.20% | ▼ −9.28% | $4.91 (−41.06%) |
Mar 26, 2026 31w ago | Press Release | $8.97 $8.41 | ▼ −6.24% | ▼ −22.31% | $4.91 (−45.26%) |
Mar 4, 2026 34w ago | Insider Cluster | $5.98 $9.64 | ▲ +61.20% | ▲ +51.12% | $4.91 (−17.89%) |
Mar 4, 2026 34w ago | Insider Cluster | $5.98 $9.64 | ▲ +61.20% | ▲ +51.12% | $4.91 (−17.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers